Hassan Nasir, DO
Allergy & Immunology · West Branch, MINPI 1376771626
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $627,180 of the $735,667 with a category attached, or 85.3%. AstraZeneca accounts for 72.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $199,820 and has fallen 59.9% since, to $80,177 in 2025. Among allergy & immunology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,225 payments — averaging $600.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$536K
- GSK$164K
- Medtronic$19K
- Amgen$10K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$507
- plus $3K from 24 others
What the payments were for
- Consulting fees$1,3480%
- Speaking & faculty fees$627,18085%
- Travel & lodging$66,3169%
- Food & beverage$21,1113%
- Education$2850%
- Other$19,4283%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 673 | $536,476 |
| GSK | 161 | $164,286 |
| Medtronic | 1 | $19,428 |
| Amgen | 108 | $10,158 |
| AbbVie | 82 | $1,405 |
| Regeneron Healthcare Solutions, Inc. | 28 | $507 |
| Novartis | 31 | $493 |
| Sanofi | 27 | $445 |
| Johnson & Johnson(2 entities) | 9 | $407 |
| ANI Pharmaceuticals, Inc. | 15 | $288 |
| Octapharma USA, Inc. | 14 | $282 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $222 |
| CSL Behring | 9 | $186 |
| Boehringer Ingelheim | 10 | $182 |
| E.r. Squibb & Sons, L.L.C. | 8 | $153 |
| Genentech USA, Inc. | 6 | $127 |
| Pfizer | 7 | $117 |
| UCB, Inc. | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Sanofi-aventis U.S. LLC | 2 | $67 |
| Aurinia Pharma U.S., Inc. | 3 | $65 |
| Phadia US Inc. | 2 | $35 |
| LEO Pharma Inc. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Hospira, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Alk-abello, Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$735,667 in reported general payments places this provider in the 95th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 86 | $565,249 |
| Humira(Cf) PenAdalimumab | 25 | $165,354 |
| TezspireTezepelumab-Ekko | 40 | $158,299 |
| NucalaMepolizumab | 39 | $134,155 |
| Enbrel SureclickEtanercept | 18 | $129,403 |
| HumiraAdalimumab | 12 | $118,346 |
| RinvoqUpadacitinib | 14 | $87,070 |
| Orencia ClickjectAbatacept | 15 | $81,958 |
| Fasenra PenBenralizumab | 13 | $74,649 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,817 |
| Hydroxychloroquine Sulfate | 111 | $3,481 |
| MethotrexateMethotrexate Sodium | 47 | $799 |
| Montelukast Sodium | 58 | $666 |
| Levocetirizine Dihydrochloride | 46 | $504 |
| Ipratropium Bromide | 17 | $498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira, Rinvoq | $1,405 | $205,41526 claims |
| AstraZenecaTezspire | $536,476 | $158,29940 claims |
| GSKNucala, Breo Ellipta | $164,286 | $138,97251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in West Branch
- Steven StrykCanton$949K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
- Jason ParisLivonia$44K
- Cem AkinNorthville$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.